New treatment paradigm of combined raloxifene and conjugated estrogen for postmenopausal symptoms in VCD-induced menopausal ratsFootnote

Peer review under responsibility of Alexandria University Faculty of Medicine.

Footnote

Available online 9 July 2016

References

• D.W.LimY.T.KimAnti-osteoporotic effects of angelica sinensis (Oliv.) Diels extract on ovariectomized rats and its oral toxicity in ratsNutrients610201443624372
   Web of Science ®Google Scholar
• A.DelmantoJ.Nahas-NetoE.A.NahasM.L.de OliveiraC.E.FernandesP.TraimanEffect of raloxifene on the vaginal epithelium of postmenopausal womenEur J Obstet Gynecol Reprod Biol1392008187192
   PubMed Web of Science ®Google Scholar
• F.H.PottooM.BhowmikD.VohoraRaloxifene protects against seizures and neurodegeneration in a mouse model mimicking epilepsy in postmenopausal womanEur J Pharm Sci652014167173
   PubMed Web of Science ®Google Scholar
• H.OhtaJ.SolankiIncorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in JapanOsteoporos Int262015849863
   Web of Science ®Google Scholar
• J.V.PinkertonF.Z.StanczykClinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophyMenopause2132014309319
   PubMed Web of Science ®Google Scholar
• B.KesselL.NachtigallL.PlouffeS.SiddhantiA.RosenA.ParsonsEffect of raloxifene on sexual function in postmenopausal womenClimacteric632003248256
   PubMed Web of Science ®Google Scholar
• S.FujiwaraE.HamayaM.SatoJ.A.FlynnR.BurgeSystematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)Clin Interv Aging9201418791893
   PubMed Web of Science ®Google Scholar
• T.GoldbergB.FidlerConjugated estrogens/bazedoxifene (Duavee): a novel agent for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosisPharm Ther4032015178182
   Google Scholar
• P.GeN.XingY.RenL.ZhuD.HanH.KuangPreventive effect of American ginseng against premature ovarian failure in a rat modelDrug Dev Res7582014521528
   Web of Science ®Google Scholar
• G.WheaterM.ElshahalyS.P.TuckV.LaarThe clinical utility of bone marker measurements in osteoporosisJ Transl Med112013201
   PubMed Web of Science ®Google Scholar
• H.R.MaJ.WangH.X.QiY.H.GaoAssessment of the estrogenic activities of chickpea (Cicer arietinum L) sprout isoflavone extract in ovariectomized ratsActa Pharmacol Sin342013380386
   PubMed Web of Science ®Google Scholar
• D.B.FarleyS.P.FordJ.P.N.RosazzaIncrease in uterine peroxidase activity in the rat uterus during oestrogen hyperaemiaJ Reprod Fertil951992551558
   PubMedGoogle Scholar
• C.MartelL.ProvencherX.LiG.LeblancS.GauthierF.LabrieBinding characteristics of novel non-steroidal antiestrogens to the rat uterine estrogen receptorsJ Steroid Biochem Mol Biol641998199205
   PubMed Web of Science ®Google Scholar
• J.AsselinP.A.KellyM.G.CaronF.LabrieControl of hormone receptor levels and growth of 7, 12-dimethylbenz(a)anthracene-induced mammary tumors by estrogens, progesterone and prolactinEndocrinology1011977666671
   PubMed Web of Science ®Google Scholar
• M.M.BradfordA rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnal Biochem721976248254
   PubMed Web of Science ®Google Scholar
• J.AndersonA.PolitchJ.PudneyI.MarquezC.MauckA quantitative glycogen assay to verify use of self-administered vaginal swabsSex Transm Dis39122015949953
   Web of Science ®Google Scholar
• W.Z.HassidS.I.AbrahamDetermination of glycogen and starchSPaKColowickNOMethods in enzymologyvol. 81957Academic PressNew York
   Google Scholar
• M.A.MoralesA.J.A.JabbagyH.P.TerenziMutations affecting accumulation of glycogenNeurospora News Lett20197324
   Google Scholar
• M.GinerM.J.RiosM.J.MontoyaM.A.VázquezC.MirandaAlendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritisEur J Pharmacol6502–32011682687
   PubMed Web of Science ®Google Scholar
• M.S.Movérare-SkrticA.E.BörjessonH.H.FarmanK.SjögrenS.H.WindahM.K.LagerquistA.AnderssonC.OhlssonThe estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is modified.Proc Natl Acad Sci USA113201411801185
   Web of Science ®Google Scholar
• A.TarantaM.BramaA.TetiG.SperaD.AgnusdeiJ.D.TermineThe selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitroBone3022002368376
   PubMed Web of Science ®Google Scholar
• E.M.MessalliC.ScaffaLong-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an updateInt J Womens Health120101120
   PubMedGoogle Scholar
• D.SaintierM.A.BurdeJ.M.ReyT.MaudelondeM.E.Cohen-Solal17 beta-estradiol downregulates beta3-integrin expression in differentiating and mature human osteoclastsJ Cell Physiol19822004269276
   Web of Science ®Google Scholar
• S.SchmidtI.NakchbandiR.RuppertN.KawelkeM.W.HessK.PfallerKindlin-3-mediated signaling from classes is required for osteoclast-mediated bone resorptionJ Cell Biol19252011883 multiple integrin 97
   PubMed Web of Science ®Google Scholar
• R.JoseC.ReyE.V.CervinoM.L.RenteroM.CasillasRaloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practiceOpen Orthop J320091421
   Google Scholar
• B.OzmenC.KirmazK.AydinS.O.KafescilerF.GucluInfluence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosisEur Cytokine Netw1832007148153
   Web of Science ®Google Scholar
• S.TakedaS.SakaiA.ShiraishiN.KoikeM.MiharaK.EndoCombination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized ratsBone5312013167173
   Web of Science ®Google Scholar
• E.M.MessalliC.ScaffaG.MaininiA.CafieroP.L.SalzilloA.RagucciRaloxifene therapy interacts with serum osteoprotegerin in postmenopausal womenMaturitas56120073844
   Web of Science ®Google Scholar
• M.A.GallantD.M.BrownM.HammondD.BlackD.JonathanStock Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material propertiesBone612014191200
   PubMed Web of Science ®Google Scholar
• E.K.StuermerS.F.DaubM.KomrakovaM.TezvalK.M.StuermerRaloxifene supports early fracture healing more than estrogen in ovariectomized ratsOsteologie42013249328
   Google Scholar
• E.M.MessalliC.ScaffaG.MaininiA.CafieroP.L.SalzilloA.RagucciRaloxifene therapy interacts with serum osteoprotegerin in postmenopausal womenMaturitas56120073844
   Web of Science ®Google Scholar
• P.HadjiTheevolutionofselectiveestrogenreceptormodulatorsinosteoporosistherapyClimactericv1562012513523
   PubMed Web of Science ®Google Scholar
• S.MartinkovichD.ShahS.L.PlaneyA.JohnJ.A.ArnottSelective estrogen receptor modulators: tissue specificity and clinical utilityClin Interv Aging9201414371452
   PubMed Web of Science ®Google Scholar
• S.E.WardellD.KazminD.P.Mc DonnellResearch resource: transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexesMol Endocrinol267201212351248
   Google Scholar
• L.BjornstromM.SjobergMechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genesMol Endocrinol192005833
   PubMed Web of Science ®Google Scholar